Skip to content

Effects of fig tea on allergic symptoms. Placebo-controlled, double-blind, randomized trial

Effects of fig tea on allergic symptoms. Placebo-controlled, double-blind, randomized trial - Anti-allergic effects of fig tea.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031048
Enrollment
10
Registered
2019-03-31
Start date
2018-01-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hay fever House dust allergy

Interventions

Drink 500 ml of fig tea daily for 8 weeks. Drink 500 ml of green tea daily for 8 weeks.

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Person who have symptoms of cedar pollinosis or house dust allergy.

Exclusion criteria

Exclusion criteria: 1)Person who has a history of diabetes, liver disease, kidney disease, gastrointestinal disease, peripheral vascular disease, other severe disease. 2)Person who has food or medicine allergy. 3)Person who plan to use medicines due to allergic rhinitis. 4)Anemia patients. 5)Overdose of alcohol. 6)Those who are planning to become pregnant or breast-feeding during the examination period 7)Participants in other clinical trials or those planning to participate. 8)Person who the attending physician determines inappropriate.

Design outcomes

Primary

MeasureTime frame
Between the test food group and the control food group, difference in amount of change in allergic symptom item at each time point after test food ingestion.

Secondary

MeasureTime frame
1) Blood biochemical test (immune related items) 2) Nasal examination 3) Symptom score of nose, eyes 4) VAS Questionnaire (Symptoms of Nose, Eyes, Skin, Mental Condition)

Countries

Japan

Contacts

Public ContactTatsuya Abe

Toyo institute of food technology Research department

tatsuya_abe@shokuken.or.jp072-740-3300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026